Vesalius Biocapital Partners
Venture capitalLuxembourg · Seed–Late Stage · 5 people tracked
Find your way into Vesalius Biocapital Partners
14 people in our graph share verified history with the Vesalius Biocapital Partners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Vesalius Biocapital Partners invests in the human health sector through venture capital funds first raised in 2007, focusing on three areas: therapeutics, medical devices, and diagnostics. The firm typically acts as lead investor in most of its financing rounds and supports companies across all development stages, including relatively early-stage projects backed by proprietary technology, strong IP, distinctive team skills, and a clear competitive edge grounded in solid data. Its portfolio companies are based in Europe, enabling close interaction with management teams.
Source: firm website, verified Aug 3, 2026.
Team · 5 people
from the firm's website
What they invest in
from 8 of 21 portfolio companiesBiotech ×6Medical Devices ×6Healthtech ×5AI & Machine Learning ×3Deep Tech ×2Digital Health ×2Hardware ×1SaaS ×1
HQs:Germany×2Belgium×1Canada×1
Investments · 21 tracked
founders shown can be your intro pathComplix develops therapeutic biologics based on Alphabody technology targeting viral diseases, oncology, and autoimmune conditions.
AI & Machine LearningBiotechDeep TechMedical Devices
Co-investorsPMVAndera PartnersGimvOmnes Capital
Exact Imaging develops the ExactVu micro-ultrasound platform, a 29 MHz imaging system that lets urologists perform real-time targeted and systematic prostate biopsies within a standard workflow.
HardwareHealthtechMedical DevicesMarkham, CA
Harold Wodlinger(Director)inRandy AuCoin(President & CEO)inRob Sandler(Executive Officer)inJerrold Wen(Executive Officer)in
BoardWilliam Wortman(Director)Gaston Matthyssens(Director)
Co-investorsiGan PartnersLumira VenturesPMVVenture Ontario
Genkyotex was a developer of NOX inhibitor therapeutics, now owned by Calliditas Therapeutics AB.
Biotech
Co-investorsAndera PartnersMC Healthcare Ventures
Genomic Vision is a genome analysis company whose Molecular Combing technology characterizes DNA at single-molecule resolution for quality control in bioproduction and cell and gene therapy, as well as for drug discovery research.
AI & Machine LearningBiotechMedical Devices
Aaron Bensimon(Chairman of the Executive Board)inFlorence Allouche(Chairman of the Supervisory Board)in
Humedics develops LiMAx, a breath analysis technology for rapid and precise measurement of liver function, enabling doctors to make tailored treatment decisions at the bedside.
BiotechDigital HealthHealthtechMedical DevicesBerlin, DE
Karsten Heyne(Co-founder)inMartin Stockmann(Co-founder)Chalom Sayada(CEO / Managing Director)
Co-investorsKfW
Ncardia develops induced pluripotent stem cell (iPSC) technologies and services for drug discovery, safety testing, and regenerative medicine applications.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Stefan Braam(Co-founder & Chief Technical Officer)inProf. Dr. MummeryProf. Dr. PassierHerman SpoldersJason Conner(Chief Executive Officer)inJeroen de Groot(Chief Operation Officer Early Discovery)in
Co-investorsCapricorn Venture Partners
OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases.
BiotechHealthtechBerlin, DE
Robert Fischer(CEO/CSO & Co-Founder)inKaren Uhlmann(Vice President Operations & IP, Co-Founder)inWolf-Hagen Schunck(Co-Founder)John R. Falck(Co-Founder)
Co-investorsRemiges Ventures, Inc.Forbion
Aptar Digital Health is a division of Aptar Pharma that designs and manufactures drug delivery systems and digital health solutions for the pharmaceutical and healthcare industries.
Digital HealthHealthtechMedical DevicesSaaS
Co-investorsEisai Innovation, Inc.KaristaSanofi Ventures
Frequently asked questions
- How many investments has Vesalius Biocapital Partners made?
- Vesalius Biocapital Partners has 21 tracked investments.
- What stage does Vesalius Biocapital Partners invest at?
- Vesalius Biocapital Partners invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Vesalius Biocapital Partners's typical check size?
- Vesalius Biocapital Partners typically writes checks of $11M.
- What sectors does Vesalius Biocapital Partners focus on?
- Vesalius Biocapital Partners focuses on Biotech, Digital Health, FoodTech, Healthtech, Medical Devices.
- Where is Vesalius Biocapital Partners located?
- Vesalius Biocapital Partners is headquartered in Luxembourg, LU.
- Does Vesalius Biocapital Partners lead rounds?
- Yes, Vesalius Biocapital Partners leads investment rounds.
- Who does Vesalius Biocapital Partners co-invest with?
- Vesalius Biocapital Partners most often shares deals with Andera Partners, Capricorn Venture Partners, Lumira Ventures, among 12 tracked co-investors.
Media · Podcasts & interviews
featuring the teamThe Value Creators with Fabienne Roussel & Guy Geldhof (Vesalius Biocapital Partners)
LPEA Luxembourg · Guy Geldhof
Similar investors
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Norwest Venture Partners is an investment firm whose growth equity team backs private, profitable, fast-growing companies, providing capital and hands-on support through its 'invited guest' approach.
Arkin Capital is a multi-asset manager overseeing more than $2 billion across venture capital, private equity, hedge funds, and real estate, operating through four arms: Arkin Health, Arkin Equity, Arkin Tech, and Arkin Real Estate.
MaRS is a Toronto-based innovation hub and accelerator that supports Canadian startups from pre-seed funding through international expansion, offering workspace, mentorship, investor and customer connections, and sector-focused programming.
Seventure Partners is a European venture capital firm, founded in 1997 and a subsidiary of Natixis Investment Managers, investing in digital technologies and life sciences companies with strong growth potential.